心臟再同步化治療市場(金額，數量，ASP):各市場區隔規模，佔有率，趨勢及SWOT分析，法律規章及償付趨勢，手術，2033年前的預測

心臟再同步治療是一種廣泛接受的選擇，可以使去同步的心臟恢復更好的生理收縮模式。二手信息證明 CRT 顯著降低了患者的發病率和死亡率。

心室不同步、室間傳導延遲、室性心動過速和心室顫動是心臟再同步治療的基石，因為它們可以顯著改善患者症狀和生存。

本報告提供全球心臟再同步化治療市場相關之詳細考察，提供市場上競爭情形，SWOT分析，到2033年前的市場預測，COVID-19影響，地區，各國趨勢等資訊。

目錄

現在上市的心臟再同步化治療和競爭情形

• 主要產業趨勢的洞察
• 心臟再同步化治療的各市場區隔整體市場收益和2015年～2033年的市場展望
• 各市場區隔的手術總數，台數，平均銷售價格，市場價值相關詳細資料

世界，地區，各國洞察

• 心臟再同步化治療市場SWOT分析
• 心臟再同步化治療市場相關競爭動態的洞察和趨勢
• 各國醫療制度概要
• 各國償付政策
• 各國醫療技術相關法規狀況

Abstract

Cardiac Resynchronisation Therapy Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast to 2033 is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.

The model discusses in detail the impact of COVID-19 on Cardiac Resynchronisation Therapy market for the year 2020 and beyond. Cardiac Resynchronisation Therapy has become a widely accepted option which restores a better physiological pattern of contractions to the desynchronized hearts. Secondary sources indicate that CRT has proven to reduce the morbidity and mortality in patients at a large scale.

Ventricular Dyssynchrony, Interventricular Conduction Delay, Ventricular Tachycardia and Ventricular Fibrillation have become the basis of Cardiac Resynchronisation Therapy as it leads to significant improvements in symptoms and survival of patients.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Cardiac Resynchronisation Therapy and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total Cardiac Resynchronisation Therapy market revenue by segment and market outlooks from 2015-2033.
• Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Cardiac Resynchronisation Therapy market.
• Competitive dynamics insights and trends provided for Cardiac Resynchronisation Therapy market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Medtronic Plc, Abbott Laboratories, Biotronik SE & Co KG, Boston Scientific Corp, MicroPort Scientific Corp, EBR Systems Inc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Cardiac Resynchronisation Therapy marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on Cardiac Resynchronisation Therapy market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Cardiac Resynchronisation Therapy market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Cardiac Resynchronisation Therapy market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Cardiac Resynchronisation Therapy market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.